In addition to reducing serum phosphorus levels to within the recommended range, ferric citrate increases iron stores.
In a study, PA21 was as efficacious as sevelamer carbonate, but patients taking PA21 had a lower pill burden and better adherence.
Researchers observed the association among individuals with serum phosphorus levels measured after fasting for 12 or more hours.
Use is associated with fewer hospitalizations versus sevelamer carbonate and calcium acetate.
In mice with and without CKD, phosphorus levels decreased by an average of 35% by 6 hours after injection with long-acting PTH.
Protein levels found to modify the effect of serum phosphorus with mortality in hemodialysis patients.
Researchers compared the novel iron-based phosphate binder with sevelamer.
In a study, nurses and technicians educated groups of hemodialysis patients about phosphate binders.
Researchers tested an intervention that included an educational fair, phosphorus group social, and staff education on phosphate binders.
Researchers observed reduced phosphorus levels in HD patients whose diet restricted intake of phosphorus additives.
Declines in serum phosphorus over time may improve survival.
Worsening or resistant hyperphosphatemia may be an under-appreciated consequence of secondary hyperparathyroidism.
Calcium-based and non-calcium-based binder use were associated with similar death risks.
Levels declined significantly from 7.2 to 5.0 mg/dL, data show.
Vascular calcification contributes to increased cardiovascular risk in dialysis patients.
New findings are consistent with those from previous animal studies.
PA21 comparable in safety and efficacy to sevelamer carbonate out to 52 weeks, study finds.
Serum levels vary throughout the day, and higher phosphorus intake exaggerates the early afternoon rise in serum phosphorus.
New findings raise questions "on the generalizability of previous research studies to the clinic setting," researchers conclude.
Low phosphorus increases all-cause and cardiovascular mortality only among the elderly.
Phosphorus levels are lower in postmenopausal women on estrogen replacement therapy.
Patients who take phosphate binders may be at a 22% higher risk of death that those who take other non-calcium based treatments.
Use of the agents is associated with a 29% and 22% decreased risk of all-cause and cardiovascular mortality.
A high proportion of top-selling grocery items contain phosphorus additives, and consumption may be encouraged by their lower cost.
It significantly decreased cardiovascular and all-cause mortality compared with calcium carbonate.
The increasing popularity of processed convenience foods could be a factor.
Consuming too much phosphorus increases the risk of left ventricular hypertrophy in women, study finds
Combined with use of a binder, this approach raised serum albumin while maintaining target phosphorus levels.
Factors unrelated to mineral metabolism may contribute to the association between high FGF-23 and death in dialysis patients.
Researchers made the discovery in a study of individuals with normal kidney function.